Literature DB >> 22401916

Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Kevin R Kozak1, Maryam Hamidi, Matthew Manning, John S Moody.   

Abstract

PURPOSE: This study examines the management and outcomes of muscle-invasive bladder cancer in the United States. METHODS AND MATERIALS: Patients with muscle-invasive bladder cancer diagnosed between 1988 and 2006 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Patients were classified according to three mutually exclusive treatment categories based on the primary initial treatment: no local management, radiotherapy, or surgery. Overall survival was assessed with Kaplan-Meier analysis and Cox models based on multiple factors including treatment utilization patterns.
RESULTS: The study population consisted of 26,851 patients. Age, sex, race, tumor grade, histology, and geographic location were associated with differences in treatment (all p < 0.01). Patients receiving definitive radiotherapy tended to be older and have less differentiated tumors than patients undergoing surgery (RT, median age 78 years old and 90.6% grade 3/4 tumors; surgery, median age 71 years old and 77.1% grade 3/4 tumors). No large shifts in treatment were seen over time, with most patients managed with surgical resection (86.3% for overall study population). Significant survival differences were observed according to initial treatment: median survival, 14 months with no definitive local treatment; 17 months with radiotherapy; and 43 months for surgery. On multivariate analysis, differences in local utilization rates of definitive radiotherapy did not demonstrate a significant effect on overall survival (hazard ratio, 1.002; 95% confidence interval, 0.999-1.005).
CONCLUSIONS: Multiple factors influence the initial treatment strategy for muscle-invasive bladder cancer, but definitive radiotherapy continues to be used infrequently. Although patients who undergo surgery fare better, a multivariable model that accounted for patient and tumor characteristics found no survival detriment to the utilization of definitive radiotherapy. These results support continued research into bladder preservation strategies and suggest that definitive radiotherapy represents a viable initial treatment strategy for those who wish to attempt to preserve their native bladder.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22401916      PMCID: PMC3351503          DOI: 10.1016/j.ijrobp.2011.12.038

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

1.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

Authors:  J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

Review 2.  Overview of bladder cancer trials in the Radiation Therapy Oncology Group.

Authors:  William U Shipley; Donald S Kaufman; William J Tester; Miljenko V Pilepich; Howard M Sandler
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

3.  Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis.

Authors:  M K Gospodarowicz; N V Hawkins; G A Rawlings; J G Connolly; M A Jewett; G M Thomas; J G Herman; P G Garrett; T Chua; W Duncan
Journal:  J Urol       Date:  1989-12       Impact factor: 7.450

Review 4.  Surgery versus radiotherapy for muscle invasive bladder cancer.

Authors:  M D Shelley; J Barber; T Wilt; M D Mason
Journal:  Cochrane Database Syst Rev       Date:  2002

5.  Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group.

Authors:  A Sell; A Jakobsen; B Nerstrøm; B L Sørensen; K Steven; H Barlebo
Journal:  Scand J Urol Nephrol Suppl       Date:  1991

6.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

7.  Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population.

Authors:  Lars Henningsohn; Kenneth Steven; Else Brohm Kallestrup; Gunnar Steineck
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

8.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

9.  Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.

Authors:  Anthony L Zietman; Dianne Sacco; Uri Skowronski; Pablo Gomery; Donald S Kaufman; Jack A Clark; James A Talcott; William U Shipley
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

Review 10.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

View more
  8 in total

1.  Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application.

Authors:  Shuo Zhang; Yong-Hua Yu; Yong Zhang; Wei Qu; Jia Li
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

2.  Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.

Authors:  Robert A Huddart; Alison Birtle; Lauren Maynard; Mark Beresford; Jane Blazeby; Jenny Donovan; John D Kelly; Tony Kirkbank; Duncan B McLaren; Graham Mead; Clare Moynihan; Raj Persad; Christopher Scrase; Rebecca Lewis; Emma Hall
Journal:  BJU Int       Date:  2017-05-29       Impact factor: 5.588

3.  Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.

Authors:  Hyun Hwan Sung; Hana Kim; Ryul Kim; Chan Kyo Kim; Ghee Young Kwon; Won Park; Wan Song; Byong Chang Jeong; Se Hoon Park
Journal:  Investig Clin Urol       Date:  2022-03

4.  Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.

Authors:  Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

5.  Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer.

Authors:  D Whalley; H Caine; P McCloud; L Guo; A Kneebone; T Eade
Journal:  Radiat Oncol       Date:  2015-09-25       Impact factor: 3.481

Review 6.  Bladder Preservation for Muscle Invasive Bladder Cancer.

Authors:  Arafat Mirza; Ananya Choudhury
Journal:  Bladder Cancer       Date:  2016-04-27

Review 7.  The Role of Population-Based Observational Research in Bladder Cancer.

Authors:  Andrew G Robinson; Jason P Izard; Christopher M Booth
Journal:  Bladder Cancer       Date:  2015-10-26

8.  Prognostic Factors for Bladder Cancer Patients in Malaysia: A Population-Based Study.

Authors:  Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali
Journal:  Int J Environ Res Public Health       Date:  2022-03-04       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.